Q and A - Challenging Cases - Video Modules - HIV Annual Update 2021 - HIV

Questions and Answers

In this on-demand webcast of a live roundtable, expert faculty consider the integrated approaches needed to address barriers to ART adherence and to select an effective new regimen for an older man with long-standing HIV infection, several comorbidities, and a complex treatment history with multiclass drug resistance. Then the expert panel discusses the best management strategies for a patient who is gaining excess weight on an INSTI- and TAF-containing first-line regimen.

Babafemi Taiwo, MBBS
Program Director

Rajesh T. Gandhi, MD

Daniel R. Kuritzkes, MD

Released: October 29, 2021

Information on this Educational Activity

Program Director

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV and funds for research support from Janssen.

Faculty

Rajesh T. Gandhi, MD

Professor of Medicine
Department of Infectious Diseases
Harvard Medical School
Physician, Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Rajesh T. Gandhi, MD, has disclosed that he has received consulting fees from Merck.

Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has disclosed that he has received funds for research support rom Atea, Gilead Sciences, Merck, Novartis, and ViiV and consulting fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Rigel, and ViiV.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

Julie Skowronski, NP

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Sarah Anderson, PharmD

Scientific Director

Sarah L. Anderson, PharmD, BCACP, BCPS, FASHP, FCCP, has no relevant conflicts of interest to report.

Target Audience

This program is intended for pathologists and other healthcare providers who treat and manage patients with lung cancer.

Goal

The goal of this activity is to improve participants’ knowledge of and competence in assessing biomarkers to guide the use of immune checkpoint inhibitors in the treatment of patients with lung cancer.

Program Medium

This program has been made available online.

Basic Principles for Challenging Scenarios in HIV Care—Pharmacist Perspectives

View ClinicalThought

Dr Rodrigo Burgos discusses managing ART for people with HIV who are heavily treatment experienced, from Clinical Care Options (CCO)

Rodrigo Burgos, PharmD, MPH Released: February 6, 2023

ClinicalThought

Proviral DNA Resistance Testing: Uses and Limitations When Switching ART

View ClinicalThought

Dr. José Arribas discusses the use of proviral DNA resistance testing when switching therapy in people with HIV, from Clinical Care Options (CCO)

José R. Arribas, MD Released: February 6, 2023

Multimedia

State of the ART: Safety and Tolerability Data Discussions From Fall 2022

View Multimedia

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP

Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

Slideset